AI-generated summary
This narrative review examines how photobiomodulation with red to near-infrared light may reprogram tumor-associated macrophages toward a pro-inflammatory state. The authors report pre-clinical evidence of M2-to-M1 shifts and enhanced CD8+ T cell infiltration when PBM is combined with checkpoint inhibitors. Because the evidence is pre-clinical and the review is narrative, clinical efficacy remains unestablished.
- Who or what was studied
- unclear
- Wavelengths
- 600, 1100 nm
- Limits stated in the abstract
- The evidence is pre-clinical and the review is narrative, so no clinical efficacy in patients is established.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 600-1100 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Reactive oxygen species, Adenosine triphosphate, Cytochrome c oxidase, Near-infrared, Angiogenesis, Nitric oxide. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.